Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo

Journal of Immunotherapy

Volumn 21, Issue 3, 1998, Pages 218-224

  Armstrong, Todd D ^a   Clements, Virginia K ^a   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Antigen presentation; CD4+ T cells; Major histocompatibility complex class II; Tumor immunity

Indexed keywords

LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOGENICITY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; TUMOR IMMUNITY;

EID: 0031898594     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199805000-00008     Document Type: Article

References (33)

1. Kern D, Klarnet J, Jensen M, Greenberg P. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 1986;136:4303-10.
2. Keene J, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982;155:768-82.
3. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990;144:4068-71.
4. Ostrand-Rosenberg S, Baskar S, Patterson N, Clements V. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 1996;47:414-21.
5. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:619-29.
6. Ostrand-Rosenberg S, Cole GA, Nishimura MI, Clements VK. Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host. Cell Immunol 1990;128:152-64.
7. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993; 90:5687-90.
8. Ostrand-Rosenberg S, Cohn A. H-2 antigen expression on teratocarcinoma cells passaged in genetically resistant mice is regulated by lymphoid cells. Proc Natl Acad Sci USA 1981;78:7106-10.
9. Ostrand-Rosenberg S, Clements V, Marr L. 402AX teratocarcinoma MHC class I antigen expression is regulated in vivo by Lytl, Lyt2, and L3T4 expressing splenic T cells. Cell Immunol 1986;98: 257-65.
10. Munro S, Pelham H. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987;48:899-907.
11. Hartley J, Crosbic J, Brink R, Kantor A, Basten A, Goodnow C. Elimination from peripheral lymphoid tissues of self reactive B lymphocytes recognizing membrane bound antigens. Nature 1991; 353:765-9.
12. Xu X, Pierce S. The novelty of antigen-processing compartments. J Immunol 1995;155:1652-4.
13. Busch R, Cloutier I, Sekaly R, Hammerling G. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996;15:418-28.
14. + tumor cells. J Immunol 1992;149:2391-6.
15. Bevan M. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 1976;117:2233-8.
16. Bevan M. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-8.
17. Lechler R, Aichinger G, Lightstone L. The endogenous pathway of MHC class II antigen presentation. Immunol Rev 1996;151:81-106.
18. Germain R, Castellino F, Han R, et al. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunol Rev 1996;151:5-30.
19. Lenschow D, Walunas T, Bluestone J. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
20. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocytes molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
21. + T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
22. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996;14:301-31.
23. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985;6:131.
24. Steimle V, Otten L, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993;75: 135-46.
25. Momburg F, Koch N, Moller P, Moldenhauer G, Butcher G, Hammerling G. Differential expression of la and la-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. J Immunol 1986;136:940-8.
26. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995;181:765-77.
27. Kern I, Steimle V, Siegrist C, Mach B. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int Immunol 1995;7:1295-9.
28. Huang A, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
29. Huang A, Bruce A, Pardoll D, Levitsky H. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-76.
30. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994;6:722-7.
31. Robbins P, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628-36.
32. Boon T, Cerrotini J, Van Pel A, van der Bruggen P. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12: 337-65.
33. Armstrong T, Clements V, Martin B, Ting J, Ostrand-Rosenberg S. MHC class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997;94:6886-91.